These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 20457590)
1. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590 [TBL] [Abstract][Full Text] [Related]
2. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920 [TBL] [Abstract][Full Text] [Related]
3. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166 [TBL] [Abstract][Full Text] [Related]
4. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709 [TBL] [Abstract][Full Text] [Related]
5. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448 [TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738 [TBL] [Abstract][Full Text] [Related]
7. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830 [TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Le Tiec C; Barrail A; Goujard C; Taburet AM Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117 [TBL] [Abstract][Full Text] [Related]
10. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924 [TBL] [Abstract][Full Text] [Related]
12. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898 [TBL] [Abstract][Full Text] [Related]
13. Atazanavir: in pediatric patients with HIV-1 infection. Deeks ED Paediatr Drugs; 2012 Apr; 14(2):131-41. PubMed ID: 22292486 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. McRae M; Clay PG; Anderson PL; Glaros AG Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947 [TBL] [Abstract][Full Text] [Related]
16. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877 [TBL] [Abstract][Full Text] [Related]
17. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771 [TBL] [Abstract][Full Text] [Related]
20. Atazanavir/ritonavir: a review of its use in HIV therapy. von Hentig N Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]